Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9671
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase |
Author: | Branford, S. Rudzki, Z. Harper, A. Grigg, A. Taylor, K. Durrant, S. Arthur, C. Browett, P. Schwarer, A. Ma, D. Seymour, J. Bradstock, K. Joske, D. Lynch, K. Gathmann, I. Hughes, T. |
Citation: | Leukemia, 2003; 17(12):2401-2409 |
Publisher: | Nature Publishing Group |
Issue Date: | 2003 |
ISSN: | 0887-6924 1476-5551 |
Abstract: | We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, P<0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN+AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P=0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN+AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC-treated patients and early measurements were predictive of subsequent response. |
Keywords: | BCR-ABL imatinib interferon alfa quantitative PCR mutation |
Description: | © 2009 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
DOI: | 10.1038/sj.leu.2403158 |
Published version: | http://www.nature.com/leu/journal/v17/n12/abs/2403158a.html |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.